Norges Bank Scholar Rock Holding Corp Transaction History

Norges Bank

$716 Trillion
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.02 - $7.76 $1.03 Million - $1.32 Million	-170,300 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$7.02 - $9.76 $1.07 Million - $1.48 Million	152,100 New	152,100 $1.38 Million
Q3 2022 Nov 13, 2023	BUY	$5.33 - $11.3 $907,699 - $1.92 Million	170,300 New	170,300 $1.1 Million
Q1 2022 May 12, 2023	BUY	$11.89 - $24.68 $5.02 Million - $10.4 Million	422,272 Added 277.63%	574,372 $7.4 Million
Q1 2022 May 09, 2022	SELL	$11.89 - $24.68 $6.83 Million - $14.2 Million	-574,372 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$24.14 - $35.18 $13.9 Million - $20.2 Million	574,372 New	574,372 $14.3 Million
Q3 2021 Nov 14, 2022	BUY	$27.38 - $42.21 $9.34 Million - $14.4 Million	341,182 New	341,182 $11.3 Million
Q3 2021 Nov 05, 2021	SELL	$27.38 - $42.21 $9.34 Million - $14.4 Million	-341,182 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$26.34 - $46.62 $8.99 Million - $15.9 Million	341,182 New	341,182 $9.86 Million
Q2 2021 Aug 10, 2021	SELL	$26.34 - $46.62 $8.99 Million - $15.9 Million	-341,182 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$45.96 - $68.02 $15.7 Million - $23.2 Million	341,182 New	341,182 $17.3 Million
Q1 2021 May 07, 2021	SELL	$45.96 - $68.02 $29 Million - $42.9 Million	-630,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$13.72 - $51.57 $8.64 Million - $32.5 Million	630,000 New	630,000 $30.6 Million
Q4 2020 Feb 10, 2021	SELL	$13.72 - $51.57 $5.56 Million - $20.9 Million	-405,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$10.54 - $18.47 $4.27 Million - $7.48 Million	405,000 New	405,000 $7.16 Million
Q3 2020 Nov 10, 2020	SELL	$10.54 - $18.47 $4.27 Million - $7.48 Million	-405,000 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$10.37 - $20.64 $4.2 Million - $8.36 Million	405,000 New	405,000 $7.38 Million
Q2 2020 Aug 07, 2020	SELL	$10.37 - $20.64 $4.2 Million - $8.36 Million	-405,000 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$9.63 - $17.14 $3.9 Million - $6.94 Million	405,000 New	405,000 $4.91 Million
Q1 2020 May 08, 2020	SELL	$9.63 - $17.14 $3.9 Million - $6.94 Million	-405,000 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$7.2 - $13.2 $2.92 Million - $5.35 Million	405,000 New	405,000 $5.34 Million
Q4 2019 Feb 12, 2020	SELL	$7.2 - $13.2 $2.92 Million - $5.35 Million	-405,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$8.95 - $15.72 $3.62 Million - $6.37 Million	405,000 New	405,000 $3.63 Million
Q3 2019 Nov 08, 2019	SELL	$8.95 - $15.72 $3.62 Million - $6.37 Million	-405,000 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$14.61 - $22.45 $5.92 Million - $9.09 Million	405,000 New	405,000 $6.42 Million
Q2 2019 Aug 09, 2019	SELL	$14.61 - $22.45 $3.73 Million - $5.72 Million	-255,000 Closed	0 $0
Q4 2018 Mar 04, 2019	BUY	$17.86 - $28.77 $4.55 Million - $7.34 Million	255,000 New	255,000 $5.86 Million
Q4 2018 Feb 08, 2019	SELL	$17.86 - $28.77 $4.55 Million - $7.34 Million	-255,000 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$13.39 - $26.25 $3.41 Million - $6.69 Million	255,000 New	255,000 $6.57 Million
Q3 2018 Nov 09, 2018	SELL	$13.39 - $26.25 $3.41 Million - $6.69 Million	-255,000 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$15.0 - $25.6 $3.83 Million - $6.53 Million	255,000 New	255,000 $3.98 Million

Others Institutions Holding SRRK

# of Institutions

175

Shares Held

75.6M

Call Options Held

585K

Put Options Held

862K

Siren, L.L.C. New York, NY

11.3M
Shares

$474 Million
4.51% of portfolio
Price T Rowe Associates Inc Baltimore, MD

8.65M
Shares

$364 Million
0.01% of portfolio
Samsara Bio Capital, LLC Palo Alto, CA

6.79M
Shares

$286 Million
31.52% of portfolio
Black Rock Inc. New York, NY

5.66M
Shares

$238 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

5.24M
Shares

$221 Million
2.74% of portfolio

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $2.17B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account